Shilpa Biocare Pvt Ltd, a subsidiary of Shilpa Medicare Limited, has entered into a strategic equity partnership with biotechnology company Gate2Brain, marking a major step forward in the development of advanced therapies for difficult-to-treat brain cancers. Under the agreement, Shilpa Biocare becomes a strategic shareholder in Gate2Brain while also providing support in chemistry, manufacturing, regulatory development and clinical advancement for the company’s lead therapeutic candidate, G2B-002.
The programme is being developed to address diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM), two aggressive forms of childhood brain cancer with limited treatment options. Both indications have received Orphan Drug Designation from regulatory authorities in the United States and Europe, reflecting the urgent need for innovative therapies in these rare diseases.
A key challenge in treating central nervous system disorders is the blood-brain barrier, a protective mechanism that restricts many medicines from reaching brain tissue. Gate2Brain’s proprietary MiniAp4 peptide shuttle technology has been designed to overcome this obstacle by transporting therapeutic compounds directly into the brain.
The company’s lead candidate combines the MiniAp4 platform with SN-38, a potent anti-cancer agent. Preclinical studies have demonstrated significantly enhanced transport of the drug into brain tissue compared with conventional approaches. First-in-human clinical studies are anticipated during fiscal year 2028.
The collaboration strengthens Shilpa Medicare’s presence in innovative oncology and specialty therapeutics while expanding its portfolio beyond traditional pharmaceutical development. It also represents the company’s fourth strategic equity investment focused on breakthrough healthcare technologies.
Market analysts note that demand for effective treatments targeting brain cancers and neurological disorders continues to grow globally. The technology platform developed by Gate2Brain may also have future applications beyond pediatric oncology, including other rare diseases and broader central nervous system conditions.
Shilpa Medicare’s leadership highlighted the differentiated nature of the brain-delivery platform and the potential to create long-term value through both therapeutic development and platform expansion. Meanwhile, Gate2Brain emphasized that the partnership provides critical manufacturing, regulatory and commercialization expertise needed to advance the programme toward clinical evaluation.
By combining innovative drug-delivery science with established pharmaceutical development capabilities, the two companies aim to accelerate progress toward new treatment options for patients facing some of the most challenging forms of brain cancer. The collaboration reflects a growing trend within the life sciences industry, where strategic partnerships are increasingly being used to advance high-potential therapies from research stages into clinical development and, ultimately, patient care.
Shilpa Medicare Limited is a leading Indian pharmaceutical company with strong capabilities across Novel Biological Entities (NBEs), complex generics, oncology active pharmaceutical ingredients (APIs), and biologics development. Backed by advanced research, development, and manufacturing infrastructure, the company collaborates with global biotechnology and pharmaceutical partners to advance innovative therapies from early-stage discovery through commercial production.
Alveolus Bio, headquartered in the United States, is focused on developing microbiota-based inhaled therapies designed to address the underlying causes of chronic respiratory diseases. The company’s pipeline targets a range of serious pulmonary conditions, including Chronic Obstructive Pulmonary Disease (COPD), Bronchopulmonary Dysplasia (BPD), Pulmonary Fibrosis, Neutrophilic Asthma, and Acute Respiratory Distress Syndrome (ARDS). Its lead therapeutic candidate is expected to enter Phase II clinical trials in the near future.
